Novotech presented to a number of biotechnology companies based at China’s SuZhou BioBay industrial park, on accessing Australia’s R&D Refund Scheme and the regulatory benefits available when undertaking early stage clinical trials in Australia. 

During the seminar, Novotech provided insights into how it supports its clients through the Australian start-up submission and approval process. 

Click to download a copy of the Frost and Sullivan White Paper ‘Australia: Preferred Destination for Early Phase Clinical Trials

For more information, click here to contact a Novotech representative.

Other relevant content